Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10569078 | 0.85 | ESR1 (0.39) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL29749402 | 0.85 | ESR1 (0.37) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL1981429 | 0.81 | ESR1 (0.37) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL5167713 | 0.78 | ESR1 (0.38) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL5047917 | 0.78 | ESR1 (0.38) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL7412155 | 0.73 | RIPK1 (0.31) | ESR1ESR2 | |
| SCHEMBL988384 | 0.72 | NR1H2 (0.48) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL15889153 | 0.72 | ESR1 (0.41) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL6013056 | 0.72 | ESR1 (0.41) | ESR1ESR2NR1H2NR1H3MAPK1 | |
| SCHEMBL702684 | 0.70 | NR1H2 (0.36) | ESR1ESR2NR1H2NR1H3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349520-A1 | SINGLY PROTECTED 2,2' -DIHYDROXYBIARYLS | EVONIK DEGUSSA GMBH (DE) | 2017-12-07 | — | — | US | claimed |
| US-8969546-B2 | Compounds useful in imaging and therapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2015-03-03 | — | — | US | claimed |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | ALBERTA HEALTH SERVICES (CA) | 2013-08-15 | — | — | US | claimed |
| EP-0409399-A1 | 3-keto HMG-COA reductase inhibitors | MERCK & CO. INC. (US) | 1991-01-23 | — | — | EP | claimed |
| US-20170349520-A1 | SINGLY PROTECTED 2,2' -DIHYDROXYBIARYLS | EVONIK DEGUSSA GMBH (DE) | 2017-12-07 | — | — | US | disclosed |
| US-8969546-B2 | Compounds useful in imaging and therapy | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2015-03-03 | — | — | US | disclosed |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | ALBERTA HEALTH SERVICES (CA) | 2013-08-15 | — | — | US | disclosed |
| EP-2017317-B1 | USE OF SELECTIVE ADSORBENTS FOR HALOGENATED AROMATIC COMPOUNDS CONTAINED IN ORGANIC MEDIA AND METHOD OF CAPTURING OF SAID HALOGENATED AROMATIC COMPOUNDS | UNIV OSAKA (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-2402300-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| WO-2011160216-A2 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2011-12-29 | — | — | WO | disclosed |
| US-20090294369-A1 | Selective Fixing Agents for Halogenated Aromatic Compounds Contained in Media and Method for Selective Fixing | OSAKA UNIVERSITY (JP) | 2009-12-03 | — | — | US | disclosed |
| EP-2067801-A1 | Synthesis of Hybrid Block Copolymers | Intezyne Technologies Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2017317-A1 | SELECTIVE STICKING AGENTS FOR HALOGENATED AROMATIC COMPOUNDS CONTAINED IN MEDIA AND METHOD FOR SELECTIVE STICKING | Neos Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2001885-A2 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007100990-A2 | OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | CONNOR DAVID THOMAS (US) | 2004-02-26 | — | — | US | disclosed |
| US-6162808-A | Compounds | ASTRAZENECA U.K. LIMITED (GB) | 2000-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038943-A1 | Indole and benzimidazole 15-lipoxygenase inhibitors | ALOX15, ALOX5, ALOX12 | ESR1 3740/4885ESR2 2032/4885NR1H2 143/4885 |
| US-20130211066-A1 | COMPOUNDS USEFUL IN IMAGING AND THERAPY | PAICS, MPI, ALDOA | ESR1 4005/4885ESR2 4403/4885NR1H2 4674/4885 |
| US-20170349520-A1 | SINGLY PROTECTED 2,2' -DIHYDROXYBIARYLS | DBH, COMT, DRD2 | ESR1 158/4885ESR2 151/4885NR1H2 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.